CHGCF (Chugai Pharmaceutical Co) Growth Rank: 9 (As of Aug. 22, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHGCF Chugai Pharmaceutical Co Ltd CHGCF
85 GF Score
Price $42.03
GF Value $47.62
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Chugai Pharmaceutical Co Growth Rank?

Chugai Pharmaceutical Co CHGCF -2.45% 85 Growth Rank is 9 as of Aug. 22, 2026, which is at its 10-year median of 9.00. GuruFocus rates CHGCF with a GF Score™ of 85/100 and a GF Value™ of $47.62 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Chugai Pharmaceutical Co has the Growth Rank of 9.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Chugai Pharmaceutical Co Growth Rank Related Terms

CHGCF vs LLY, JNJ, ABBV: Growth Rank Comparison

For the Drug Manufacturers - General subindustry, Chugai Pharmaceutical Co's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chugai Pharmaceutical Co Growth Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chugai Pharmaceutical Co's Growth Rank distribution charts can be found below:

* The bar in red indicates where Chugai Pharmaceutical Co's Growth Rank falls into.


CHGCF
85GF Score
Chugai Pharmaceutical Co Ltd CHGCF
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 9 mean?
Chugai Pharmaceutical Co (CHGCF) has a Growth Rank of 9 as of Aug. 22, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Chugai Pharmaceutical Co and its competitors. This is near median its historical median of 9.00. Over the past decade, Chugai Pharmaceutical Co's Growth Rank has ranged from 2.00 to 10.00.
Is Chugai Pharmaceutical Co's Growth Rank too high?
Chugai Pharmaceutical Co's current Growth Rank of 9 is near median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Chugai Pharmaceutical Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Growth Rank compare to LLY and JNJ?
Chugai Pharmaceutical Co's Growth Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, Chugai Pharmaceutical Co's own Growth Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Drug Manufacturers company?
A good Growth Rank depends on the Drug Manufacturers industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Growth Rank is 9, which is near median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCF) is currently considered Modestly Undervalued. The stock's GF Value™ is $47.62, compared to a current price of $42.03 — trading 11.7% below its estimated fair value. The current Growth Rank is 9, which is near median its 10-year median of 9.00. Chugai Pharmaceutical Co's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCF), the current Growth Rank is 9 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chugai Pharmaceutical Co (CHGCF) Overvalued in 2026?

Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued. The current stock price of $42.03 is trading 11.7% below its estimated GF Value™ of $47.62. GuruFocus considers Chugai Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for CHGCF:

  • Growth Rank: 9 (near median its 10-year median of 9.00)
  • GF Value™: $47.62 vs. price of $42.03 (11.7% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the CHGCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chugai Pharmaceutical Co Business Description

Address 2-1-1 Muromachi, Nihonbashi, 12th Floor, Nihonbashi Mitsui Tower, Chuo-ku, Tokyo, JPN, 103-8324
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
85GF Score

Get the complete analysis for CHGCF

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$42.03
Price
$47.62
GF Value